ABBVIE
A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2017-10-19
- Last Posted Date
- 2024-06-17
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 156
- Registration Number
- NCT03314181
- Locations
- 🇦🇺
Eastern Health /ID# 165850, Box Hill, Victoria, Australia
🇨🇦Cross Cancer Institute /ID# 203114, Edmonton, Alberta, Canada
🇯🇵Kameda General Hospital /ID# 225246, Kamogawa-shi, Chiba, Japan
A Study to Evaluate the Safety and Pharmacokinetics ABBV-399 in Japanese Participants With Solid Tumors
- Conditions
- Advanced Solid Tumors Cancer
- Interventions
- Drug: ABBV-399
- First Posted Date
- 2017-10-17
- Last Posted Date
- 2019-03-14
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 9
- Registration Number
- NCT03311477
- Locations
- 🇯🇵
National Cancer Center Hospital /ID# 166939, Chuo-ku, Tokyo, Japan
🇯🇵Shizuoka Cancer Center /ID# 166940, Sunto-gun, Shizuoka, Japan
A Study Assessing the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Participants in Japan
- First Posted Date
- 2017-10-17
- Last Posted Date
- 2021-03-09
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 22
- Registration Number
- NCT03311464
- Locations
- 🇯🇵
Nagoya City University Hospital /ID# 164510, Nagoya-shi, Aichi, Japan
🇯🇵Juntendo University Urayasu Hospital /ID# 164422, Urayasu Shi, Chiba, Japan
🇯🇵Fukuoka University Hospital /ID# 164416, Fukuoka-shi, Fukuoka, Japan
Study to Describe the Management and the Use of Healthcare Resources in Patients With Chronic Lymphocytic Leukemia (CLL) Initiating Venetoclax in Routine Clinical Practice
- Conditions
- Chronic Lymphocytic Leukemia
- First Posted Date
- 2017-10-16
- Last Posted Date
- 2023-03-30
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 93
- Registration Number
- NCT03310190
- Locations
- 🇨🇦
The Moncton Hospital /ID# 166043, Moncton, New Brunswick, Canada
🇨🇦Jack Ady Cancer Centre /ID# 217491, Lethbridge, Alberta, Canada
🇨🇦Jewish General Hospital /ID# 166418, Montreal, Quebec, Canada
Study of the Effectiveness and Clinical Practice Use of Glecaprevir Plus Pibrentasvir in Patients With Chronic Hepatitis C Genotypes 1 to 6
- Conditions
- Hepatitis C
- First Posted Date
- 2017-10-06
- Last Posted Date
- 2021-05-19
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 2118
- Registration Number
- NCT03303599
- Locations
- 🇮🇹
Azienda Ospedaliero - Universi /ID# 168130, Pisa, Italy
🇵🇱NZOZ Przychodnia Specjalistycz /ID# 208334, Zychlin, Lodzkie, Poland
🇵🇱Szpital Wojewodzki w Opolu /ID# 208444, Opole, Opolskie, Poland
Long-Term Safety Study of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women
- Conditions
- Uterine FibroidsHeavy Menstrual Bleeding
- Interventions
- First Posted Date
- 2017-09-05
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 478
- Registration Number
- NCT03271489
- Locations
- 🇺🇸
Exordia Medical Research, Inc /ID# 160853, Fall River, Massachusetts, United States
🇺🇸Health care Affiliates Medical Group /ID# 163324, Santa Ana, California, United States
🇺🇸Duplicate_Northwell Health System - Manhasset /ID# 201058, Manhasset, New York, United States
A Post-Marketing-Observational Study (PMOS) to Determine the Effectiveness of Combined Adalimumab Treatment and Active Supervised Training in Patients With Axial Spondyloarthritis (axSpA)
- Conditions
- Axial Spondyloarthritis
- Interventions
- Behavioral: Active Supervised Training (AST)Behavioral: Standard of Care (SOC) Physiotherapy
- First Posted Date
- 2017-08-23
- Last Posted Date
- 2019-10-02
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 17
- Registration Number
- NCT03258814
- Locations
- 🇩🇪
Rheumahaus Studien GbR, Potsdam, DE /ID# 164494, Potsdam, Brandenburg, Germany
🇩🇪MVZ Wittenbergplatz PP Orthos /ID# 204802, Berlin, Germany
🇩🇪Rheumapraxis /ID# 164461, Halle, Germany
A Study to Assess the Efficacy of Risankizumab Compared to FUMADERM® in Subjects With Moderate to Severe Plaque Psoriasis Who Are Naïve to and Candidates for Systemic Therapy
- First Posted Date
- 2017-08-21
- Last Posted Date
- 2019-09-13
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 120
- Registration Number
- NCT03255382
- Locations
- 🇩🇪
Universitaetsklinik Heidelberg /ID# 161014, Heidelberg, Baden-Wuerttemberg, Germany
🇩🇪Universitatsklinikum Frankfurt /ID# 161036, Frankfurt, Hessen, Germany
🇩🇪Johannes Wesling Klin Minden /ID# 161015, Minden, Nordrhein-Westfalen, Germany
A Study of SC-007 in Subjects With Advanced Cancer
- Conditions
- Colorectal Cancer (CRC)Gastric Cancer
- Interventions
- Drug: SC-007
- First Posted Date
- 2017-08-17
- Last Posted Date
- 2018-04-27
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 7
- Registration Number
- NCT03253185
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Washington University-School of Medicine, Saint Louis, Missouri, United States
🇺🇸Gabrail Cancer Center Research, Canton, Ohio, United States
A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
- Conditions
- MalignanciesAcute Lymphoblastic Leukemia (ALL)Acute Myeloid Leukemia (AML)Non-Hodgkin's LymphomaNeuroblastoma
- Interventions
- Drug: chemotherapyDrug: venetoclax
- First Posted Date
- 2017-08-02
- Last Posted Date
- 2023-05-22
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 143
- Registration Number
- NCT03236857
- Locations
- 🇫🇷
AP-HM - Hopital de la Timone /ID# 161465, Marseille CEDEX 05, Bouches-du-Rhone, France
🇺🇸Memorial Sloan Kettering Cancer Center-Koch Center /ID# 163444, New York, New York, United States
🇫🇷Robert Debre Hopital, FR /ID# 161464, Paris, France